Bharat Parenterals
BSE 541096
9 stories, newest first.
- Shareholders approve preferential share issue and higher Section 186(2) limits
- Bharat Parenterals schedules Q2 & H1FY27 earnings conference call for October 30, 2026
- Board meeting on October 29 to consider and approve September quarter and half year results
- EGM summary: preferential equity issue and Section 186 limit approval among 2 special resolutions
- Innoxel Lifesciences, Bharat Parenterals' subsidiary, begins U.S. commercial supply with its first CMO product
- Corrigendum to EGM Notice: Preferential Issue Over INR 100 crore; Crisil Named Monitoring Agency
- EGM on October 23, 2026 to consider preferential issue of 9,12,759 shares and higher Section 186 limits
- Board approves Rs. 138.99 crore preferential issue of 9,12,759 shares to 15 non-promoter investors
- Board Meeting on 29 September 2026 to Consider Fund Raising via Preferential Issue
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.